Ivabradine Accord

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Accord (Ivabradine)

Q: What conditions is Ivabradine Accord used to treat?

Ivabradine Accord is prescribed for chronic stable angina pectoris and for heart failure with reduced ejection fraction (NYHA class II–III). In both settings the drug lowers heart rate, helping to reduce angina episodes and improve functional capacity in heart‑failure patients.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, which is responsible for spontaneous pacemaker activity. By inhibiting this current, the drug slows the rate of depolarisation during phase 4, resulting in a reduced heart rate without affecting contractility or blood pressure.

Q: What is the usual dose of Ivabradine Accord?

The specific dose of Ivabradine Accord is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerability. Dosage adjustments are made according to therapeutic response and any observed adverse effects.

Q: Is Ivabradine Accord safe to use during pregnancy or breastfeeding?

Ivabradine is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Breastfeeding is not recommended unless the benefit outweighs the risk.

Q: How do I order Ivabradine Accord from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers for heart‑rate control?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can reduce contractility and blood pressure, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Q: What are the recommended storage conditions for Ivabradine Accord?

Ivabradine Accord should be stored at temperatures below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Q: How is Ivabradine Accord administered?

Ivabradine Accord is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically aligned with the patient’s daily routine to maintain consistent plasma concentrations.

Q: What are the most serious risks associated with ivabradine therapy?

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and heart block. Patients should be monitored for signs of excessive heart‑rate reduction, arrhythmias, or marked drops in blood pressure, and therapy should be discontinued if these events occur.

Q: Who should not use Ivabradine Accord?

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, severe hypotension, sick

Ivabradine, the active ingredient in Ivabradine Accord, is a If channel inhibitor presented as an oral tablet for oral use. It is used to treat chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients who require heart‑rate reduction without affecting contractility.

GNH India supplies Ivabradine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine is indicated for conditions where heart‑rate reduction improves clinical outcomes.

Chronic stable angina pectoris: decreases the frequency of angina attacks by lowering heart rate.
Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and reduces hospitalisation risk.
Elevated resting heart rate in patients with coronary artery disease: helps control heart rate when beta‑blockers are insufficient or not tolerated.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which slows spontaneous depolarisation. By reducing the slope of phase 4 depolarisation, the drug lowers heart rate without altering myocardial contractility, ventricular repolarisation, or blood pressure, thereby improving myocardial oxygen balance in angina and reducing workload in heart failure.

Side Effects

Adverse reactions may occur with ivabradine therapy.

Common Side Effects

Bradycardia: heart rate below the therapeutic range.
Visual disturbances (phosphenes): transient luminous phenomena.
Headache.
Dizziness.
Fatigue.
Blurred vision.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical intervention.
Atrial fibrillation or other arrhythmias.
Severe hypotension.
Symptomatic heart block.
Persistent visual impairment.
Allergic reactions including rash or angioedema.

Precautions & Warnings

Before initiating ivabradine, clinicians should consider several safety measures.

Baseline heart‑rate monitoring: ensure resting heart rate is ≥60 bpm before starting.
Severe hypotension: avoid use in patients with systolic BP <90 mmHg.
Sick sinus syndrome or AV block: contraindicated unless a pacemaker is present.
Hepatic impairment: dose adjustment may be required.
Pregnancy category B: use only if potential benefit justifies the risk.
Store at below 25°C: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Ivabradine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels.
Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce ivabradine exposure.
Concurrent bradycardic agents (beta‑blockers, digoxin, verapamil, diltiazem): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise ivabradine concentrations.

Antacids containing aluminum or magnesium: can affect oral absorption; separate administration by at least 2 hours.
Alcohol: may potentiate bradycardic effects and should be used cautiously.

Frequently Asked Questions

Ivabradine Accord is prescribed for chronic stable angina pectoris and for heart failure with reduced ejection fraction (NYHA class II–III). In both settings the drug lowers heart rate, helping to reduce angina episodes and improve functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, which is responsible for spontaneous pacemaker activity. By inhibiting this current, the drug slows the rate of depolarisation during phase 4, resulting in a reduced heart rate without affecting contractility or blood pressure.

The specific dose of Ivabradine Accord is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate target, and tolerability. Dosage adjustments are made according to therapeutic response and any observed adverse effects.

Ivabradine is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Breastfeeding is not recommended unless the benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can reduce contractility and blood pressure, making ivabradine a useful alternative when beta‑blockers are contraindicated or not tolerated.

Ivabradine Accord should be stored at temperatures below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Ivabradine Accord is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically aligned with the patient’s daily routine to maintain consistent plasma concentrations.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and heart block. Patients should be monitored for signs of excessive heart‑rate reduction, arrhythmias, or marked drops in blood pressure, and therapy should be discontinued if these events occur.

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, severe hypotension, sick

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.